Modality
Degrader
MOA
AuroraAi
Target
PARP
Pathway
PD-1/PD-L1
NMOSD
Development Pipeline
Preclinical
~Mar 2018
→ ~Jun 2019
Phase 1
~Sep 2019
→ ~Dec 2020
Phase 2
~Mar 2021
→ ~Jun 2022
Phase 3
~Sep 2022
→ ~Dec 2023
NDA/BLA
Mar 2024
→ Nov 2027
NDA/BLACurrent
NCT03356737
577 pts·NMOSD
2024-03→2027-11·Completed
577 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-241.7y awayPh3 Readout· NMOSD
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2027-11-24 · 1.7y away
NMOSD
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03356737 | NDA/BLA | NMOSD | Completed | 577 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| BGN-6990 | BeiGene | Phase 2/3 | BCMA | |
| Semasacituzumab | Jazz Pharma | Phase 2 | AHR |